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will never become clinically apparent during their life-
time, many men are unnecessarily exposed to the risks of
treatment.1, 10–12 This ongoing debate has divided the
medical community over whether PSA screening is
more likely to lead to net benefit or harm.
The complexity of information needed to make an
educated decision about PSA screening has led to quali-
ty improvement methods7 and educational interven-
tions15–24 to enhance PSA counseling. PSA educational
interventions are reported to improve postintervention
knowledge, but do not have a consistent effect on inten-
tion to be screened, even in men who have never been
tested.15–19, 22–24 In fact, despite increasing literature on the
outcomes of counseling interventions, it is not clear how
patients use the information given in counseling.25, 26
Patients may not understand detailed risk information
to the extent implied by practice guidelines,25, 27, 28 and
their perception of risk can be affected by the perceived
severity of the cancer,29 individual values,16, 30 or the
counselor’s framing of the communicated information.31
A better understanding of how patients process screen-
ing information presented by their physicians is funda-
mental to improving decision making.
The purpose of this study was to examine the
process of decision making after PSA counseling.
Because a fixed-answer instrument might overlook atti-
tudes that we had not anticipated,32, 33 we developed an
open-ended interview of how men use information
about PSA screening. 
Methods
This study used open-ended interviews and qualitative
methods to examine PSA decision making. Design and
analysis of the study are outlined in Figure 1. The
University of Michigan Institutional Review Board
approved all methods and materials.
Participants
Participants were recruited by two complementary meth-
ods: newspaper advertisements and direct mail to prima-
ry care patients. The newspaper advertisements solicited
men 40 to 65 years of age to participate in a study about
“patient decision making” without mentioning PSA test-
ing. Advertising respondents were enrolled on a first-
called, first-enrolled basis. For primary care patients, a
letter was sent to 200 men randomly selected from an
administrative database search of men 40 to 65 years of
age with a recent health maintenance visit to an internist
or family physician. Men who voluntarily responded to
the letter were enrolled. Telephone calls were made to a
random sample of nonresponders, with oversampling for
African Americans to ensure sufficient representation.
Men with cancer, patients of the interviewer, physicians,
and allied health care professionals were excluded from
both pools. Recruitment continued from both pools until
no new themes arose within the most recent interviews—
that is, the point of thematic “saturation.”33 Participants
were compensated at $10 per hour.
Interview
Each participant was interviewed by a single facilitator in
a 60- to 120-minute, in-person session using written mate-
rials and a structured script of open-ended questions.
Interviews were divided into three segments: the precoun-
seling assessment, the counseling intervention, and the
postcounseling assessment (Figure 1). Recordings of all
three segments of each interview were transcribed for sub-
sequent analysis.
The precounseling segment, approximately 5 to 10
minutes in duration, consisted of a written survey that
included demographics and history of screening for
prostate cancer and a one-on-one discussion about the
participant’s experience with prostate cancer screening,
his general preferences for relationships with his physi-
cian, and his approach to medical decision making. 
The counseling session was designed to be similar
to the best-case experience envisioned in guidelines,
including an interactive format, ability to use either
numerical or nonnumerical language, and extended time
for the participant’s questions. The content of counseling
(Table 1) centered around two main messages. The first
message was that medical science as a whole (as reflected
in consensus guidelines) is uncertain about whether rou-
tine PSA screening is effective and that individual physi-
cians are divided about the value of screening. The sec-
ond message was that estimating the likelihood of net
benefit versus harm to an individual undergoing PSA
screening requires weighing and valuing the risk for
death or disability from prostate cancer (a risk that may
be greater among unscreened men) and the risk for
incontinence, impotence, or infection after treatment for
cancer that, if left untreated, may or may not have proved
to be aggressive (a risk that will be greater among
screened men). This latter concept was conveyed to par-
ticipants by hand drawing a simplified decision tree with
estimated probabilities of the various good or bad out-
comes. In addition, the counseling intervention included
information about prostate cancer epidemiology, natural
history (including prevalence in autopsy studies), and the
estimated probabilities of true-positive, false-positive,
and false-negative results of PSA testing. 
Counseling continued until the participant voiced
his understanding, which was usually between 2 to 10
minutes but occasionally was longer. All information
and risk information was derived from published guide-
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ly lasted more than an hour for the more enthusiastic
and talkative participants.
Analysis
Over 1200 pages of interview transcripts were analyzed
using accepted methods from grounded theory36 and
content analysis.37 All three authors read a subset of
transcripts to find common themes that occurred across
several interviews. The authors discussed their findings
and used three-way consensus to derive themes directly
from participant quotes. These themes were used to
develop a systematic structure of “codes,” which was
applied by two authors. The coding process used Atlas
software (Scholari Software, Thousand Oaks, CA) to
assist in a line-by-line reading of the transcripts to iden-
tify quotes that either supported or contradicted the
identified themes.
We followed several steps to ensure trustworthi-
ness, which is a concept in qualitative research roughly
analogous to validity and reliability in quantitative
research.38 The interviewers used restatement to verify
that the participant agreed with the interviewers’ inter-
pretations. The authors reviewed the transcripts inde-
pendently. The analysis and resulting themes were
reviewed by experts in the fields of decision making,
ethics, internal medicine, family medicine, and urology.
Participants recall of previous PSA screening was veri-
fied with a review of electronic laboratory records from
the laboratory systems of two local hospitals.
Results
The complementary recruiting method reached themat-
ic saturation by the 16th advertising participant and the
24th mail respondent, for a total of 40 participants. Table
2 describes baseline characteristics of the study partici-
pants. Thirty participants (75%) either reported prior
PSA screening or were found to have had a PSA test
according to electronic records of one of three local hos-
pital systems. After counseling, 37 participants (93%)
said the intervention contained information that they
interpreted as being unfavorable for PSA screening.
However, 29 of 30 men (97%) who had had PSA screen-
ing favored testing in the future (Figure 2), although
only 2 of 10 men (20%) without prior screening intend-
ed to be tested in the future. 
Transcript analysis focused on how participants
used the risk–benefit information to decide whether to
be tested. Many men considered PSA screening in the
context of benefits or harms from treatment of a hypo-
thetical case of cancer in the future, as envisioned by
guidelines,1–7 instead of considering only the conse-
quences of the blood test itself. However, we were sur-
prised to find that many men who said they interpreted
the counseled information as unfavorable subsequently
discounted the validity or applicability of the new infor-
mation. Most of the dismissive beliefs fell into one of the
seven thematic categories shown in Tables 3 and 4. Some
beliefs (four of the seven) were cited by men regardless
of their later-stated intention for or against PSA screen-
*BPH = benign prostatic hypertrophy.
TABLE 1













Description of terms: prostate,
prostate cancer, BPH.
Prostate cancer is common.
Some cancers are very aggressive;
most are indolent (don’t cause 
problems).
No tests can distinguish between
aggressive and indolent cancer until
after aggressive cancer has spread.
Screening can identify prostate cancer
in an early stage, when treatment
may be less difficult. 
Early detection may save lives.
False-positive screening results can
occur.
Prostate biopsy has risks (e.g., 
infection).
Detection may result in unnecessary
treatment of cancers that would not
have caused symptoms in patient’s 
lifetime.
Substantial harms of early prostate
cancer treatment (e.g., impotence,
incontinence) can occur.
At present, it is unclear if screening
men for prostate cancer will lead 
to benefit or harm for individuals
tested.
Results of large trials may help but
are years away from a definitive 
conclusion about the utility of PSA.
Medical experts recommend that men
considering testing be counseled
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therefore the benefits of PSA must outweigh the risks
(“Enthusiasm for PSA as ‘good prevention’”). A few men
who favored PSA testing complained about a history of
bad luck and claimed they needed a PSA test specifically
to protect against their tendency for misfortune (“PSA is
protection against ‘bad luck’”). Many men were simply
committed to “more information” or “knowing,” even if
its usefulness might be obscure (“Valuing PSA as knowl-
edge for its own sake”).
Discussion
Because most published guidelines advocate patient
counseling before consideration of PSA screening, we
sought to describe men’s reactions to and use of infor-
mation provided during an “ideal” counseling session.
Much of the prior work regarding patient decision mak-
ing and PSA screening has focused on evaluating the
outcomes, in terms of men’s knowledge and screening
*Totals do not equal the number in each group because participants may have multiple or no officially tallied beliefs.
TABLE 3
Underlying Beliefs Cited by Men Regardless of Plan for Future PSA Screening*
DESCRIPTION OF BELIEFS
Fear of “The Big C” (cancer) , n (%)
“Most people would be too influenced by fear [of cancer] to decide.”
“I’d be too afraid of cancer . . . I could never look at the numbers and decide 
like I do at work.”
“I understand about [the low risk for morbidity and mortality with a positive 
PSA], but there is still a chance. I wouldn’t be able to sleep, think or even 
take a dump without worrying about that cancer. It would HAVE to come 
out! . . . My wife would make me take it out.”
Salient anecdotes and analogies, n (%)
“Hey! That’s a sensitive area! I don’t want to end up impotent like [a friend].”
“I have had friends that have had the prostate operation, and [became] 
incontinent!”
“I think my impression initially was that [my physician] didn’t want to do the 
test, and I insisted that we do it . . . I think about Bo Schembechler, he had 
a prostate operation, and [a co-worker] . . . and somebody else, too, 
a pretty renowned citizen—oh! General Schwarzkopf.”
Distrust of statistics, n (%)
“All that doesn’t matter. The real issue is whether you want to have cancer. 
If you do, by all means listen to statistics. If you don’t, get the test!”
“It would be interfering with a sacred relationship between a man and his 
doc . . . I want to know that my doctor is thinking about me, not some  
other 100,000 guys.”
Faith in science, n (%)
“There will be another test that the medical community will come up with in 
the future that will work better than the PSA . . . If I don’t get the PSA, then 
I won’t know to get that [other] test, I won’t be able to benefit from the 
advance . . . There was a time when the PSA didn’t exist men were subject 
to cancer without warning. Now, the PSA is here, and something else will 
be discovered soon.”
“[PSA] is a tool, right now there isn’t anything else . . . unless the testing is 
there for them to see, what can come of it? These screenings and testings 
are going to lead to results down the road, possibly new treatments, 













PLANNING FUTURE PSA SCREENING
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behavior, of a specific decision aid administered to a
sample of men.16–24 In contrast, the goal of this study was
to investigate the processes and reasoning involved in
patient decision making. The interview provided a best-
case scenario for the informed decision making envi-
sioned in guidelines. We found that men’s underlying
beliefs and prior testing appeared to influence intentions
toward future screening more than a weighing of com-
municated risks and benefits.
Interpretations
Most men who had been tested intended to be tested
again. Some men may have felt a general confidence in
the soundness of their previous decisions or that the new
information did not differ sufficiently from what they
remembered to justify a new appraisal. It may be that
because such underlying beliefs are formed over a peri-
od of months or years, a single intervention or doctor
visit is insufficient to impact the participant’s intention.
Although we have assumed that the underlying beliefs
were similar to the “prior beliefs” reported to interfere
in other studies of communication,39, 40 another explana-
tion is that they could have formed anew in reaction to
unexpected negative information. 
An alternative is that the influence of beliefs is
somewhat similar to heuristic thinking,41 where early
impressions interfere with appraisal of new information.
A traditional approach to many of these influences might
be to intensify or repeat counseling to minimize “errors”
in appraisal of scientific evidence. This approach may be
misplaced, because many beliefs are not necessarily judg-
ment errors to be eradicated. For example, participant
*Total does not equal the number in the group because participants may have multiple or no officially tallied beliefs.
TABLE 4
Underlying Beliefs Cited Only by Men Planning Future PSA Screening*
DESCRIPTION OF BELIEF
Enthusiasm for PSA as “good prevention”, n (%)
“I honestly believe the knowing, and having the option of prevention, outweighs all the other 
risks . . . risk doesn’t matter, you gotta do the proper things for health anyway.”
“Now, if they don’t get a PSA, and then they get [cancer], I have no sympathy for ‘em. That’s 
just stupid on their part, they could have prevented it, but didn’t . . . Why should we pay for 
their unnecessary medical care? It’s their doctor’s fault, too—a doctor is supposed to prevent 
things, not ignore them!”
“I’ve been blessed with good health, for the most part, and I just did not want to run the risk. I 
didn’t want to do something stupid . . . if there’s a test, or an exam or something, I’m going to 
take it . . . I just want to be preventive, instead of regretting after the fact. My body’s like a 
[car], if the oil’s low, I’ll go ahead and change it. It’s by taking preventive measures like this 
I’ve been able to maintain a reasonable amount of good health . . . God knows I try to live 
right, do right . . . I try within reason to do the things that I know I should.”
PSA is protection against “bad luck”, n (%)
“I don’t think MOST people should have a PSA . . . I still want it because bad things happen 
to me. I am always the guy with bad luck, the one percent . . . I’ll get cancer because I get 
everything else.”
“I’m not impressed with the numbers . . . I’m always in the slowest supermarket line. I’m 
always in the slowest expressway lane. I’m always in the minority anyways, so you’re telling 
me 80% of people will get better if you follow this procedure, it doesn’t tell me what is going 
to happen for me.”
Valuing PSA as knowledge for its own sake, n (%)
“I still like the idea of doing the blood test, only because I’m curious about these things.”
“Well, I still find [PSA] interesting—I like to do the analysis thing, like I used to do with 
[work] . . . so I like to see results. But if I get a positive result, I’m not sure I’ll do anything.”







reliance on “salient anecdotes” does not invalidate the
importance of listening to others’ experiences in making
decisions. It also seems unlikely that any educational
intervention will change a basic belief in “bad luck.”
Finally, some beliefs are the direct result of widely dis-
seminated media messages for cancer screening; for
example, some men quoted the slogan, “get the test,” or
used the misapplied term prevention. Despite their origin
or prevalence, underlying beliefs have the potential to
limit consideration of the risk–benefit information that
clinicians are asked to present to patients. 
Comparison with Other Studies
Many published studies of pamphlets and videotaped
decision aids15–23 report an improvement in knowledge
about prostate cancer screening but also report variable
effects on the rate of subsequent PSA testing. Many of
these studies took place in a relatively controlled, super-
vised setting and, therefore, may not be generalizable to
typical community practice settings. In contrast, a single
effectiveness study24 conducted in a variety of practice
settings enrolled a group of men nearly half of whom
had previous PSA testing; the study failed to show a sig-
nificant effect on either knowledge or subsequent PSA
screening.
Given the variety of these studies, it is difficult to
make sweeping generalizations about the value of PSA
decision aids, especially for a diverse patient population
with a range of education, socioeconomic status, or desire
for shared decision making. As a result, physicians are
left with the traditional responsibility of appraising and
communicating individual risk, one patient at a time.
The chief value of the current qualitative study is to
point out how even this type of individualized approach
could be rendered less effective by the patient’s experi-
ence with PSA screening.
Limitations
Qualitative methods are associated with small sample
sizes that do not allow for confidence in the ability to
generalize conclusions, although the data are possibly
richer than those of a larger survey. In our study, the use
of a single interviewer was helpful to maintain consis-
tency in counseling content but may have affected
response diversity. Selection bias is often a problem with
studies involving volunteer participants,42 but our study
reduced such bias by using two complementary recruit-
ing strategies that avoided mention of PSA screening.
The underlying beliefs that we uncovered may be
more common in some populations than in others.
Although this study included men with a wide range of
income and education, the relatively high mean income
and education level differ from other reported work on
decisions and PSA screening.15 The frequent discussions
of PSA screening in the media could have resulted in a
“contamination” effect. The results may not generalize
well to patients who have never heard of PSA screening
or who have never been tested, such as men in Wolf’s
1996 study.15 On the other hand, men who have never
heard of PSA may be increasingly rare in an era domi-
nated by the Internet and widespread advertising for
PSA testing.43 Some commentators may argue that
highly educated or informed men may be more facile
with decision making and interpreting medical evi-
dence, but such a disparity in shared decision making
argues more for a need for communication methods
than against the existence of underlying beliefs. 
Remaining Questions
Differences in intention toward future PSA screening
between men with and without prior testing could
argue for counseling before men learn about PSA
screening from other sources, such as the Internet,
advertisements in the mass media, or friends and fami-
ly. On the other hand, counseling efforts are unlikely to
compete well with messages promoting screening by the
media and local hospitals, which have the advantage of
marketing experience and solid funding. Given the cur-
rently low rates of counseling25, 26 and limitations in
patient understanding of counseled information,25–29, 31
efforts to better understand patient experiences with
counseling might be more advisable than further pro-
moting noninteractive decision aids17–20, 23, 24 or encour-
aging documentation of counseling in patient records.7
Because shared decision making involves at least two
participants sharing information and building consen-
sus,44 further study of persuasive communication should
determine at what point clinician counselor efforts to
clarify “misunderstandings” become persuasion or even
coercive trespassing on patient rights.
This study is not meant to be a call for paternalism
or against counseling. Rather, we suggest that consensus
panels understand the limits of office communication
before advising deferral of uncertain decisions to indi-
vidual patients. It seems unlikely that simply giving
more information to the patient will solve problems
inherent to informed consent.45 Regardless of origin or
prevalence, prior or other underlying beliefs can limit
consideration of the risk–benefit information that clini-
cians are asked to present to patients. Perhaps decision
aids and other efforts to optimize counseling15–24 may
not contribute as meaningfully as some evaluations sug-
gest, especially in an uncontrolled setting, or when men
have been previously tested or have previous knowledge
about PSA. Clinicians who wish to have full patient par-
ticipation in uncertain decisions should elicit prior expe-
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riences before counseling. Further investigation of the
ability of physicians or decision aids to briefly assess and
discuss the prior or underlying beliefs of individual
patients will be valuable to current policy about PSA
testing and future policy about other upcoming tests.
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